News GSK suffers a setback with its TIM-3 programme GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.
News Bayer files HER2+ lung cancer drug in China Bayer files its oral HER2+ lung cancer drug in China, as it extends a race to market with rival Boehringer Ingelheim.
News Survival data back Tagrisso's role in first-line lung cancer Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?
News Dizal set to bring lung cancer drug Zegfrovy to US Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.
News Nuvalent chases after Nuvation in ROS1 lung cancer New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.
News AZ, Daiichi get Datroway nod in lung cancer on second try AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.
News Scribe Therapeutics joins the IPO queue Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
